Madrigal Pharmaceuticals MDGL announced an exclusive global licensing agreement with Suzhou Ribo Life Science Co. Ltd. (Ribo) and its subsidiary, Ribocure Pharmaceuticals AB (Ribocure), covering six ...

The potentially $4.4 billion deal is Madrigal’s second with a China-based biotech and hands the company six preclinical RNA ...

Company advances its leadership in MASH with an expanded pipeline, which now includes more than 10 programs at multiple stages of development, ...

Elevated lipoprotein(a) concentrations are associated with atherosclerotic cardiovascular disease. The safety and efficacy of lepodisiran, an extended-duration, small interfering RNA targeting hepatic ...

Ohio State University researchers develop RNA micelles, offering targeted chemotherapy for metastatic colorectal cancer.

Feb 11 (Reuters) - Madrigal Pharmaceuticals said on Wednesday it has entered into a global licensing deal with China-based Suzhou Ribo Life Science for six preclinical small interfering RNA programs ...

Despite the availability of effective antihypertensive therapies, global blood pressure control rates remain unacceptably low. Contributing factors, such as low treatment adherence, therapeutic ...

Vanscoy Rare Pharmacy, a leading specialty pharmacy focused on supporting people living with rare conditions, announced today that it has been selected as the exclusive specialty pharmacy provider for ...

The discovery of siRNA and its role in RNAi was a groundbreaking finding in the field of molecular biology. In 1998, Andrew Fire and Craig Mello published a seminal paper describing the phenomenon of ...

Researchers have developed RNA therapeutics, called micelles, that can delivery chemotherapeutic drugs to metastasized tumors in mouse models.

Please provide your email address to receive an email when new articles are posted on . In this video, Yancy, a professor and chief of cardiology at Northwestern University Feinberg School of Medicine ...